215 related articles for article (PubMed ID: 32680651)
1. Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy.
Tian C; Wong BL; Hornung L; Khoury JC; Rybalsky I; Shellenbarger KC; Rutter MM
Neuromuscul Disord; 2020 Jul; 30(7):599-610. PubMed ID: 32680651
[TBL] [Abstract][Full Text] [Related]
2. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.
Tian C; Wong BL; Hornung L; Khoury JC; Miller L; Bange J; Rybalsky I; Rutter MM
Neuromuscul Disord; 2016 Nov; 26(11):760-767. PubMed ID: 27614576
[TBL] [Abstract][Full Text] [Related]
3. The effect of oral bisphosphonate therapy on vertebral morphometry and fractures in patients with Duchenne muscular dystrophy and glucocorticoid-induced osteoporosis.
Nasomyont N; Tian C; Hornung L; Khoury J; Hochwalt PM; Tilden JC; Wong BL; Rutter MM
Muscle Nerve; 2021 Dec; 64(6):710-716. PubMed ID: 34506040
[TBL] [Abstract][Full Text] [Related]
4. Bone density and alendronate effects in Duchenne muscular dystrophy patients.
Houston C; Mathews K; Shibli-Rahhal A
Muscle Nerve; 2014 Apr; 49(4):506-11. PubMed ID: 23835890
[TBL] [Abstract][Full Text] [Related]
5. The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy.
Sbrocchi AM; Rauch F; Jacob P; McCormick A; McMillan HJ; Matzinger MA; Ward LM
Osteoporos Int; 2012 Nov; 23(11):2703-11. PubMed ID: 22297733
[TBL] [Abstract][Full Text] [Related]
6. Effects of Bisphosphonates on Osteoporosis Induced by Duchenne Muscular Dystrophy: A Prospective Study.
Zheng WB; Dai Y; Hu J; Zhao DC; Wang O; Jiang Y; Xia WB; Xing XP; Li M
Endocr Pract; 2020 Dec; 26(12):1477-1485. PubMed ID: 33471740
[TBL] [Abstract][Full Text] [Related]
7. Risk factors associated with prevalent vertebral fractures in Duchenne muscular dystrophy.
Phung K; McAdam L; Ma J; McMillan HJ; Jackowski S; Scharke M; Matzinger MA; Shenouda N; Koujok K; Jaremko JL; Smit K; Walker S; Hartigan C; Khan N; Konji VN; MacLeay L; Page M; Sykes E; Robinson ME; Alos N; Cummings EA; Ho J; Sbrocchi AM; Stein R; Saleh D; Craven BC; Dang UJ; Siminoski K; Rauch F; Ward LM
Osteoporos Int; 2023 Jan; 34(1):147-160. PubMed ID: 36342539
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of teriparatide treatment for severe osteoporosis in patients with Duchenne muscular dystrophy.
Nasomyont N; Keefe C; Tian C; Hornung L; Khoury J; Tilden JC; Hochwalt P; Jackson E; Rybalsky I; Wong BL; Rutter MM
Osteoporos Int; 2020 Dec; 31(12):2449-2459. PubMed ID: 32676823
[TBL] [Abstract][Full Text] [Related]
9. Use of weekly alendronate to treat osteoporosis in boys with muscular dystrophy.
Apkon S; Coll J
Am J Phys Med Rehabil; 2008 Feb; 87(2):139-43. PubMed ID: 17912140
[TBL] [Abstract][Full Text] [Related]
10. Randomized Controlled Trial Evaluating the Use of Zoledronic Acid in Duchenne Muscular Dystrophy.
Zacharin M; Lim A; Gryllakis J; Siafarikas A; Jefferies C; Briody J; Heather N; Pitkin J; Emmanuel J; Lee KJ; Wang X; Simm PJ; Munns CF
J Clin Endocrinol Metab; 2021 Jul; 106(8):2328-2342. PubMed ID: 33954789
[TBL] [Abstract][Full Text] [Related]
11. The time to and determinants of first fractures in boys with Duchenne muscular dystrophy.
Ma J; McMillan HJ; Karagüzel G; Goodin C; Wasson J; Matzinger MA; DesClouds P; Cram D; Page M; Konji VN; Lentle B; Ward LM
Osteoporos Int; 2017 Feb; 28(2):597-608. PubMed ID: 27774565
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study.
Moretti A; Liguori S; Paoletta M; Gimigliano F; Iolascon G
Adv Ther; 2022 Jul; 39(7):3308-3315. PubMed ID: 35614293
[TBL] [Abstract][Full Text] [Related]
13. Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.
Tamechika SY; Sasaki K; Hayami Y; Ohmura SI; Maeda S; Iwagaitsu S; Naniwa T
Arch Osteoporos; 2018 Jun; 13(1):67. PubMed ID: 29904824
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Denosumab for Glucocorticoid-Induced Osteoporosis in an Adolescent Patient with Duchenne Muscular Dystrophy: A Case Report.
Kumaki D; Nakamura Y; Sakai N; Kosho T; Nakamura A; Hirabayashi S; Suzuki T; Kamimura M; Kato H
JBJS Case Connect; 2018; 8(2):e22. PubMed ID: 29642113
[TBL] [Abstract][Full Text] [Related]
15. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R
N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
[TBL] [Abstract][Full Text] [Related]
16. Bone density and bone health alteration in boys with Duchenne Muscular Dystrophy: a prospective observational study.
Suthar R; Reddy BVC; Malviya M; Sirari T; Attri SV; Patial A; Tageja M; Didwal G; Khandelwal NK; Saini AG; Saini L; Sahu JK; Dayal D; Sankhyan N
J Pediatr Endocrinol Metab; 2021 May; 34(5):573-581. PubMed ID: 33838091
[TBL] [Abstract][Full Text] [Related]
17. [Alendronate treatment of osteoporosis secondary to Duchenne muscular dystrophy].
Palomo Atance E; Ballester Herrera MJ; Márquez de La Plata MA; Medina Cano E; Carmona Vilchez RM
An Pediatr (Barc); 2011 Feb; 74(2):122-5. PubMed ID: 21169073
[TBL] [Abstract][Full Text] [Related]
18. Different bone health progression patterns and early-stage risk marker in glucocorticoid-treated ambulatory Duchenne muscular dystrophy.
Zhou L; Zhou H; Xu H; Sun X; Chen X; Fan P; Cai X; Wang Q
Osteoporos Int; 2024 Jun; 35(6):997-1005. PubMed ID: 38277031
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic oral bisphosphonate therapy in duchenne muscular dystrophy.
Srinivasan R; Rawlings D; Wood CL; Cheetham T; Moreno AC; Mayhew A; Eagle M; Guglieri M; Straub V; Owen C; Bushby K; Sarkozy A
Muscle Nerve; 2016 Jun; 54(1):79-85. PubMed ID: 26599341
[TBL] [Abstract][Full Text] [Related]
20. Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial.
Jensen TW; Hansen MS; Hørslev-Petersen K; Hyldstrup L; Abrahamsen B; Langdahl B; Zerahn B; Pødenphant J; Stengaard-Petersen K; Junker P; Østergaard M; Lottenburger T; Ellingsen T; Andersen LS; Hansen I; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen AJ; Tarp U; Lindegaard H; Jurik AG; Vestergaard A; Hetland ML;
Ann Rheum Dis; 2014 Jun; 73(6):1123-9. PubMed ID: 23661492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]